R&D News | pharmaphorum

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

News

J&J adds rare disease wAIHA to Imaavy's potential uses

Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.

News

Novartis gets win for another Avidity muscular dystrophy AOC

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

Anthropic puts life sciences at heart of new AI model

Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

J&J adds rare disease wAIHA to Imaavy's potential uses

Novartis gets win for another Avidity muscular dystrophy AOC

Anthropic puts life sciences at heart of new AI model

SonoThera's $125m Series B heads recent biofinancings

Cancer biotech Parabilis books record IPO, raising $670m

ESMO26: Neoadjuvant Enhertu fails in early breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks